Evidence map›Paper›PMID 30610196›Full record

ArticleBlood cancer journal2019

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Jonathan L Kaufman, Roberto Mina, Andrzej J Jakubowiak, Todd L Zimmerman, Jeffrey J Wolf, Colleen Lewis, Charise Gleason, Cathy Sharp, Thomas Martin, Leonard T Heffner and 3 more

Registry-linked trialAbstract readClinical Trial, Phase IMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01549431 (A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma), which is not on this map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01549431 phase1completednot on this map

A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma

TypeinterventionalSponsorEmory UniversityRan2012 to 2017Enrolled32ConditionsMultiple MyelomaArmsPanobinostat, Carfilzomib, Dexamethasone
3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. [Research progress on protein lactylation modification in malignant tumors].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Review
  7. Review
  8. Review
  9. Histone deacetylase in inflammatory bowel disease: novel insights.Therapeutic advances in gastroenterology · 2025
    Review
  10. Review
  11. Review
  12. Review
  13. Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer.International journal of molecular sciences · 2024
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jonathan L KaufmanHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA. jlkaufm@emory.edu.
Roberto MinaHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Andrzej J JakubowiakUniversity of Chicago Medical Center, Chicago, IL, USA.
Todd L ZimmermanUniversity of Chicago Medical Center, Chicago, IL, USA.
Jeffrey J WolfUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Colleen LewisHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Charise GleasonHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Cathy SharpHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Thomas MartinUCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
Leonard T HeffnerHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Ajay K NookaHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
R Donald HarveyHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
Sagar LonialHematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maximum tolerated dose (MTD) of the combination (CarPan) and assess safety and efficacy among RRMM patients. Thirty-two patients (median of 4 prior lines of therapy) were enrolled. The MTD was carfilzomib 36 mg/m

Indexed as

AgedAntineoplastic Combined Chemotherapy ProtocolsDrug Resistance, NeoplasmFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMultiple MyelomaOdds RatioOligopeptidesPanobinostatRecurrenceRetreatmentTreatment OutcomecarfilzomibOligopeptidesPanobinostat

Identifiers

PMID30610196
PMCPMC6320362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.